The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Triggers typically occur when portfolio drift exceeds a set threshold or on a scheduled interval, prompting a rebalance to restore targets.
15,940 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Across a century and a half, Western Union has defined cross-border payments. Yet fintech competition and shifting co...
Prospect Capital offers a striking 20%+ yield, but its long-run performance raises questions. This article lays out a...
A closer look at how Lawrence Calcano built iCapital into a leading wealth-tech platform for alternatives. Learn the ...
This guide helps you understand the drivers behind the group (rily) 2025 earnings for BRC Group under RILY. It breaks...
Institutional investors are eyeing Millrose Properties’ land-banking model as the housing market shifts. This look at...
Investors weighed the promise of Milestone Pharmaceuticals against the realities of a high-stakes biotech market. Thi...
As investors scan the horizon for regenerative medicine players, Avita (RCEL) faces a pivotal quarter. This guide bre...
A large fund sold a sizable stake, and the stock still lagged the market. This look breaks down what happened, why it...
Chewy, crowned america’s best brand america’s in a 2026 reputation poll, faces a sharp stock drop as brand strength f...
When Berkshire Hathaway named Greg Abel to lead investments, the portfolio made a surprising pivot. This article brea...
Critics have labeled this stock as overvalued for years, yet its price action and earnings trajectory tell a differen...